Human Albumin Administration in Subarachnoid Hemorrhage: Results of an International Survey

• Published in: Neurocritical care 2014-04, Vol.20 (2), p.277-286
• Main Authors: Suarez, Jose I., Martin, Renee H., Calvillo, Eusebia, Zygun, David, Flower, Oliver, Wong, George K., Bershad, Eric M., Venkatasubba Rao, Chethan P., Georgiadis, Alexandros, Jichici, Draga, Leroux, Peter D.
• Format: Article
• Language: English
• Subjects: Adult; Clinical Protocols; Clinical trials; Critical care; Critical Care - methods; Critical Care Medicine; Health Care Surveys; Hemorrhage; Humans; Hypotension; Intensive; Intensive care; Internal Medicine; Medicine; Medicine & Public Health; Mortality; Neurology; Neurology - methods; Neuroprotective Agents - administration & dosage; Neuroprotective Agents - therapeutic use; Nurses; Onsite; Original Article; Patients; Physicians; Practice Patterns, Physicians' - statistics & numerical data; Serum Albumin - administration & dosage; Serum Albumin - therapeutic use; Serum Albumin, Human; Statistical analysis; Stroke; Subarachnoid Hemorrhage - drug therapy
• ISSN: 1541-6933; 1556-0961
• DOI: 10.1007/s12028-013-9942-y

Background Subarachnoid hemorrhage (SAH) is a devastating disease. Nimodipine is the only medical treatment shown to improve outcome of SAH patients. Human albumin (ALB) may exert neuroprotection in SAH. However, current usage of ALB in SAH is not known. We conducted an international survey of clinicians involved in the care of SAH patients to determine current practice of ALB administration in SAH. Methods We constructed a 27-question survey. Our sampling frame consisted of neurointensivists, general intensivists, neurocritical care nurses, critical care pharmacists, and neurosurgeons. The survey was available from 11/15/2012 to 12/15/2012. We performed mostly descriptive statistical analysis. Results We obtained 362 responses from a diverse range of world regions. Most respondents were intensivist physicians (88 %), who worked in academic institutions (73.5 %) with a bed capacity >500 (64.1 %) and an established institutional management protocol for SAH patients (70.2 %). Most respondents (83.5 %) indicated that their institutions do not incorporate ALB in their protocol, but half of them (45.9 %) indicated using ALB outside it. ALB administration is influenced by several factors: geographic variation (more common among US respondents); institutions with a dedicated neuroICU; and availability of SAH management protocol. Most respondents (75 %) indicated that a clinical trial to test the efficacy of ALB in SAH is needed. Conclusions In this survey we found that ALB administration in SAH patients is common and influenced by several factors. Majority of respondents support a randomized clinical trial to determine the safety and efficacy of ALB administration in SAH patients.